Sudocetaxel zendusortide is a proprietary PDC, linked to docetaxel, a well-established and well-characterized cytotoxic agent. The U.S. Food and Drug Administration (FDA) recently granted fast track designation to sudocetaxel zendusortide to be developed as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy. Sudocetaxel zendusortide is the Company’s lead PDC stemming from Theratechnologies’ SORT1+ Technology™ in oncology.

Sudocetaxel zendusortide is currently being evaluated in a Phase 1 clinical trial.

Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, is the Principal Investigator of the Phase 1 trial for sudocetaxel zendusortide.

The detailed Phase 1 study protocol is available at www.clinicaltrials.gov under the identifier number: NCT04706962.